Intellia Therapeutics, Inc. (NASDAQ: NTLA) priced a public offering of 16,744,187 shares of its common stock at $10.75 per share on April 29 2026, generating gross proceeds of approximately $180 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering was underwritten by Jefferies, Goldman Sachs & Co. LLC, and Citigroup, with a 30‑day option to buy up to 2,511,628 additional shares at the offering price.
The offering price represented an 18.6% discount to the prior day’s closing price of $13.04 and was upsized from an initial $150 million target to $180 million in response to strong demand. The underwriters’ option allows them to purchase additional shares at the same price, potentially increasing the total proceeds if exercised.
Intellia intends to use the proceeds to fund clinical development and prepare for the commercial launch of its lead programs, lonvo‑z for hereditary angioedema and nex‑z for transthyretin amyloidosis. The company’s cash position was $605.1 million as of December 31 2025 and $517.2 million as of March 31 2026, and the new capital is expected to extend the company’s runway into the second half of 2027.
Financially, Intellia reported a net loss of $95.8 million for Q4 2025, an improvement from the $128.9 million loss in Q4 2024, while negative free cash flow of $396 million over the last twelve months underscored the need for additional liquidity. The offering provides a critical infusion of capital to sustain operations and advance the pipeline.
The pricing of the offering at a discount, combined with the upsizing and the underwriters’ option, reflects current market conditions and investor appetite. As a major financing event for a clinical‑stage biopharmaceutical company, the transaction is material and will influence the company’s financial trajectory and strategic execution.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.